By Priyanjana Pramanik, MSc. Reviewed by Susha Cheriyedath, M.Sc. Feb 11 2026 New SELECT trial insights suggest semaglutide’s cardiovascular protection goes beyond weight loss, pointing to broader cardiometabolic mechanisms and reshaping how clinicians may view GLP-1 therapies. Study: Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial . Image Credit: Edugrafo / Shutterstock In a recent study published in  The